Click Therapeutics Raises $50M Series D to Commercialize CT‑155 Digital Therapeutic

Why It Matters

These investments fast‑track the rollout of novel digital therapies, AI‑driven financial tools, and wearable bone‑health devices, reshaping care delivery, revenue management, and preventive health in the industry.

Key Takeaways

• Click Therapeutics secures $50M Series D from Boehringer Ingelheim
• CT‑155 targets schizophrenia symptoms and holds FDA Breakthrough Device status
• Joyful Health raises $17M to scale AI‑driven revenue‑cycle platform
• Osteoboost Health obtains $8M to expand wearable vibration therapy
• All three deals signal rising investor confidence in health‑tech innovation

Pulse Analysis

The $50 million Series D that Click Therapeutics raised from Boehringer Ingelheim marks a pivotal moment for the digital‑therapeutics sector. CT‑155, a prescription‑grade software classified as an FDA Breakthrough Device, targets core symptoms of schizophrenia in adults, a condition with limited pharmacologic options. By transferring commercialization rights to Click, Boehringer leverages its drug‑development expertise while allowing a nimble tech partner to drive market rollout. This collaboration reflects a broader pharma trend of investing in software‑based treatments that can be rapidly iterated and scaled alongside traditional medicines.

Joyful Health’s $17 million Series A, led by CRV, underscores the rising demand for AI‑driven revenue‑cycle solutions in a fragmented healthcare finance landscape. The platform ingests claims data, identifies billing anomalies, and automates recovery workflows, promising to reclaim millions of dollars lost to inefficiencies. As providers adopt electronic health records and value‑based contracts, the need for a unified, analytics‑rich infrastructure becomes critical. Investors are betting that such technology will not only improve cash flow but also enable providers to focus resources on patient care rather than administrative bottlenecks.

The $8 million financing round for Osteoboost Health positions the company to accelerate clinical validation and scale manufacturing of its FDA‑cleared wearable that delivers low‑frequency vibration to the lumbar spine and hips. Early studies suggest that such mechanical stimulation can increase bone density in osteopenia patients, potentially delaying progression to osteoporosis—a condition that costs the U.S. healthcare system billions annually. By combining a consumer‑friendly device with rigorous clinical data, Osteoboost taps into the growing preventive‑care market, where wearables are increasingly used to address chronic disease risk before it manifests.

Deal Summary

Digital therapeutic firm Click Therapeutics announced a $50 million Series D round led by Boehringer Ingelheim. The funding will support the commercialization of its CT‑155 prescription digital therapeutic for schizophrenia, with Boehringer also transferring marketing responsibilities to Click.